Compare · CV vs TMDX
CV vs TMDX
Side-by-side comparison of CapsoVision Inc. (CV) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.00B, about 9.4x CV ($318.8M).
- Over the past year, CV is up 78.0% and TMDX is down 21.0% - CV leads by 99.0 points.
- CV has been more active in the news (4 items in the past 4 weeks vs 3 for TMDX).
- TMDX has more recent analyst coverage (19 ratings vs 3 for CV).
- Company
- CapsoVision Inc.
- TransMedics Group Inc.
- Price
- $6.56+2.98%
- $85.10-1.49%
- Market cap
- $318.8M
- $3.00B
- 1M return
- -0.61%
- -4.80%
- 1Y return
- +78.02%
- -21.02%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2019
- News (4w)
- 4
- 3
- Recent ratings
- 3
- 19
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest CV
- CapsoVision to Participate in Upcoming Investor Conferences
- Roth Capital resumed coverage on CapsoVision with a new price target
- SEC Form EFFECT filed by CapsoVision Inc.
- SEC Form 424B5 filed by CapsoVision Inc.
- SEC Form S-3 filed by CapsoVision Inc.
- SEC Form 10-Q filed by CapsoVision Inc.
- CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- CapsoVision Reports Second Quarter 2026 Financial Results
- CapsoVision® Announces International Launch of AI Highlights
- CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026
Latest TMDX
- TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026